Northwest Biotherapeutics CTO Dr. Marnix Bosch revealed that independent statisticians re-examined the company’s DCVax-L trial results using individual patient-level data (IPD) from multiple randomized controlled trials. By applying propensity score matching and inverse probability weighting, the researchers found a median survival advantage ranging from 3.4 to 6.3 months. These figures represent a significant increase over the 2.8-month advantage reported in the original cohort-level analysis.
Northwest Biotherapeutics Reports Stronger Survival Data for DCVax-L
Updated statistical analysis of the Phase III trial for DCVax-L indicates that the survival benefits for glioblastoma patients were likely underestimated in original findings. Presented at the British Neuro-Oncology Society meeting, the new data utilizes individual patient-level records to provide a more precise look at treatment efficacy.
To ensure the robustness of these findings, the team performed sensitivity analyses, including E-Values and Rosenbaum’s Gamma measures. These tests confirmed that the observed treatment effects were not the result of hidden imbalances between the DCVax-L group and the control patients. According to Bosch, the consistency across different statistical approaches reinforces the clinical value of the therapy, which is currently undergoing regulatory review for commercial approval in the United Kingdom.
Comments (0)
No comments yet. Be the first!